2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Johnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.Peer-Reviewed Original ResearchExpression of immune checkpointsClinical activityNeoadjuvant cisplatinImmune checkpointsT cellsIncreased expression of immune checkpointsTranscriptome RNA sequencingMuscle-invasive patientsPegfilgrastim 6 mgAggressive histologic subtypePathological complete responseUrothelial bladder cancerT cell genesBasal-squamousYpCR rateNeoadjuvant therapyComplete responseHistological subtypesSingle-institutionUrothelial cancerPrimary endpointUrothelial tumorsTumor biologyBladder cancerGrade 3
2017
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiation
2007
The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer
Jain A, Haisfield-Wolfe ME, Lange J, Ahuja N, Khouri N, Tsangaris T, Zhang Z, Balch C, Jacobs LK. The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer. Annals Of Surgical Oncology 2007, 15: 462-471. PMID: 17985188, DOI: 10.1245/s10434-007-9623-1.Peer-Reviewed Original ResearchConceptsUltrasound-guided fine-needle aspirationSentinel node dissectionAxillary node dissectionPreoperative ultrasound-guided fine-needle aspirationPositive predictive valuePrimary tumor featuresFine-needle aspirationAxillary nodesNode dissectionTumor featuresAbnormal axillary nodesBreast cancer patientsLymph node pathologyPrimary breast tumorsRole of ultrasoundSuspicious nodesNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseDefinitive managementCancer patientsBreast cancerPredictive valueBreast tumorsUSFNA results